| Thu, Nov 26, 2009 | | | CytRx Announces First of Two Positive Developments Ahead at Seeking Alpha (Thu 5:17am)
| | Tue, Nov 24, 2009 | | | CytRx Announces Plan to Initiate a Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Soft Tissue Sarcomas Business Wire (Tue, Nov 24)
| | | CytRx Corporation: Key Developments Ahead at Seeking Alpha (Tue, Nov 24)
| | Mon, Nov 23, 2009 | | | Pending Key Developments Ahead for CytRx Corporation (NASDAQ: CYTR) Marketwire (Mon, Nov 23)
| | | CytRx: Technical Breakout Imminent at Seeking Alpha (Mon, Nov 23)
| | Wed, Nov 18, 2009 | | | CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer Business Wire (Wed, Nov 18)
| | Fri, Nov 13, 2009 | | | CYTRX CORP Financials EDGAR Online Financials (Fri, Nov 13)
| | Mon, Nov 9, 2009 | | | CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online (Mon, Nov 9)
| | | CYTRX CORP Files SEC form 10-Q, Quarterly Report EDGAR Online (Mon, Nov 9)
| | | CytRx Reports 2009 Third Quarter Financial Results Business Wire (Mon, Nov 9)
| | Wed, Oct 28, 2009 | | | CytRx Announces Publication of Paper Stating that Chaperone Amplification Represents a 'Significant Strategy' in Anti-aging Pharmaceutical Design Business Wire (Wed, Oct 28)
| | Thu, Oct 15, 2009 | | | CYTRX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online (Thu, Oct 15)
| | Tue, Oct 13, 2009 | | | CytRx Fortifies Executive Suite with Addition of Chief Medical Officer Business Wire (Tue, Oct 13)
| | Mon, Sep 14, 2009 | | | CytRx and Cephalon Oncology Therapies to be Evaluated as Treatment for Relapsed Acute Promyelocytic Leukemia Business Wire (Mon, Sep 14)
| | Thu, Sep 10, 2009 | | | CytRx Secures Key European Patent for Arimoclomol Business Wire (Thu, Sep 10)
| | Wed, Sep 9, 2009 | | | Correction: CytRx FDA letter AP (Wed, Sep 9)
| | | CytRx to Present at the Sachs Associates Annual Biotech in Europe Investor Forum Business Wire (Wed, Sep 9)
| | | CytRx to repsond to FDA letter in 4Q at bizjournals.com (Wed, Sep 9)
| | Tue, Sep 8, 2009 | | | CytRx expects to file FDA response in 4Q AP (Tue, Sep 8)
| | | CytRx Receives FDA Letter Regarding Arimoclomol Phase IIb Clinical Trial for ALS Business Wire (Tue, Sep 8)
| Add CYTR News to My Yahoo!:

| |
|